Bangalore, India, May 07, 2025 – OneSource Specialty Pharma Limited (BSE:544292, NSE: ONESOURCE) today announced its consolidated financial results for the quarter (Q4FY25) and full year ended March 31, 2025
Financial Highlights (In ₹ million)
| Particulars | Q4FY25 | Q4FY243 | YoY | FY25 | FY243 | YoY |
| Revenues | 4,260 | 3,436 | 22% | 14,449 | 10,821 | 30% |
| EBITDA | 1,825 | 1,004 | 79% | 4,665 | 2,247 | 104% |
| EBITDA % | 43% | 29% | 1362 bps | 32% | 21% | 1165 bps |
| PAT | 992 | (112) | 100%+ | 9361 | (2,280) | 100%+ |
| Adjusted EPS | 12.22 | 2.32 | 100%+ | 21.42 | (7.9) | 100%+ |
- FY25 PAT excludes exceptional one-time scheme related expenses in YTD Q3’25 and FY25 of ₹ 1,108m
- Adjusted EPS = Excluding exceptional items & Scheme amortization
- Prior period numbers are presented proforma basis. The prior period numbers have been reclassified to align with the current period to make it comparable
Mr. Neeraj Sharma, CEO & MD, OneSource Specialty Pharma Limited speaking on the performance said, “We’re delighted to announce a 30% revenue increase, driven by all-round robust growth. EBITDA grew significantly due to product mix in favour of Drug Device Combinations (DDCs) and Biologics, and higher operational efficiencies. Our business has been driven by strong customer acquisition and new MSAs. With the successful on-going integration of the acquired entities, we’re achieving cross-selling opportunities, and cost synergies, creating greater value for customers and shareholders.”
 reports strong FY25 results with 30% revenue growth, 104% EBITDA growth, and return to profitability driven by Biologics and Drug Device Combinations.){kind=link}